MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug ...

Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...

Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its ...

AI/ML technologies are revolutionizing pharmaceutical formulation by optimizing excipient selection and predicting stability, reducing time and resources needed for development. Poor solubility of ...

Formulation scientists are behind the conversion of active pharmaceutical ingredients (API) into stable, bioavailable, and commercially viable dosage forms, rarely a simple process. Image Credit: ...

The protein therapeutics market totaled $63 billion in 2007 ($39 billion in the U.S. alone) and is expected to reach $87 billion by 2010, according to a report by Kalorama Information—“Protein ...

CRDMOs offer a continuum of services from early discovery to clinical manufacturing, addressing solubility and stability challenges in NCE development. Advanced technologies like spray drying and ...

Early on, the drug substance (DS) manufacturer will provide a wealth of preliminary characterization data. And if the drug is active in early nonclinical and preclinical testing, a larger quantity of ...

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human ...

The MarketWatch News Department was not involved in the creation of this content. AI-driven robotics platform reduces drug formulation development time from years to months SACRAMENTO, Calif., May 19, ...

Drug formulation is becoming increasingly complex. Poorly soluble APIs, personalized medicines, and advanced oral dosage forms require production methods that are scalable, reproducible, and precise.

first biocompatible pharmaceutical formulations progress to preclinical models new sustained-release drug delivery platforms for peptides, melanocortins aim to predict drug release kinetics from new ...